MEF2D and non-small cell lung carcinoma: Studies in vitro have shown an anti-cancer function of miR-218, and the down-expression of miR-218 increases myocyte enhancer factor 2D (MEF2D) levels by promoting lung cancer growth [57], and by inhibiting NSCLC proliferation and metastasis via by downregulating CDCP1 [58].